Drug price advocates targeting CEO compensation

Drug price control advocates are signaling their intention to inject CEO compensation into their messaging. In a commentary published Monday, Patients for Affordable Drugs President David Mitchell juxtaposed the cost burden on families of cystic fibrosis patients from an unidentified drug from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) with the compensation of that company's President, Chairman and CEO Jeffrey Leiden. The commentary said the drug costs $259,000 annually, while Leiden received $28 million in 2015 compensation...